Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia

BSE1105.05-0.85 (-0.08 %)

PREV CLOSE ( ) 1105.90

OPEN PRICE ( ) 1097.75

BID PRICE (QTY) 1105.90 (6)

OFFER PRICE (QTY) 1107.65 (31)

VOLUME 4464

TODAY'S LOW / HIGH ( )1088.35 1113.95

52 WK LOW / HIGH ( )823.7 1309

NSE1106.800.8 (+0.07 %)

PREV CLOSE( ) 1106.00

OPEN PRICE ( ) 1099.30

BID PRICE (QTY) 1106.50 (103)

OFFER PRICE (QTY) 1106.80 (9)

VOLUME 88956

TODAY'S LOW / HIGH( ) 1086.50 1114.80

52 WK LOW / HIGH ( )802 1309.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1978

Management Info

Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director

Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details

Alankit Assignments Ltd.

205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi

Listing : BSE, NSE

NEWS

02Sep Jubilant Pharmova completes transfer o
Jubilant Pharmova has successfully completed the sale and transfer of it..

02Sep Jubilant Pharmova gains on completing
Jubilant Pharmova is currently trading at Rs 1047.95, up by 8.45 points..

02Aug Jubilant Pharmova informs about commun
Jubilant Pharmova has informed that it enclosed a communication pursuant..

02Aug USFDA concludes PAI at Jubilant Pharm
United States Food and Drug Administration (USFDA) has concluded pre-app..

30Jul Jubilant Pharmova informs about newspa
Pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligat..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	58	192
Gross Profit	65	376
Operating Profit	110	1317
Net Sales	595	7457

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Glenmark Pharma (BSE) 2114.10 (2.99%)	M.Cap ( in Cr)59651.61
Gland Pharma (BSE) 1919.35 (2.72%)	M.Cap ( in Cr)31613.46
Acutaas Chemicals (BSE) 1507.35 (2.68%)	M.Cap ( in Cr)12322.91
Dr. Reddy's Lab (BSE) 1288.80 (3.08%)	M.Cap ( in Cr)107514.11
Wockhardt (BSE) 1493.20 (2.30%)	M.Cap ( in Cr)24332.39

Shareholding Pattern

	PROMOTERS	47.68%
	NON-INSTITUTION	25.4%
	MUTUAL FUNDS/UTI	6.01%
	FI/BANKS/INSURANCE	1.15%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Kotak Healthcare Fu...	3.74
Kotak Special Oppor...	3.72
Kotak Consumption F...	2.55
Kotak MNC Fund-Reg(G)	1.92
HDFC Pharma and Hea...	1.75
Bandhan Innovation ...	1.59
Bajaj Finserv Healt...	1.27

Risk Disclosures on Derivatives

Smart Quotes

JUBILANT PHARMOVA LTD.